| TOP | termination of pregnancy; topoisomerase |
|---|---|
| top | topical |
| CCC | care-cure coordination; cathodal closure contraction; chronic calculous cholecystitis; chronic catar... |
| PCA | para-chloramphetamine; parietal cell antibody; passive cutaneous anaphylaxis; patient care assistant... |
| PCC | Pasteur Culture Collection; percutaneous cecostomy; pheochromocytoma; phosphate carrier compound; pl... |
| gene products, vif | A 23 kD regulatory protein important for virion infectivity in HIV. The protein is found in the cytoplasm of HIV-infected cells and is not absolutely required for virion formation. (12 Dec 1998) |
|---|---|
| gene products, vpr | Trans-acting proteins which accelerate virus replication in HIV. The vpr proteins act in trans to increase the levels of HIV specified proteins. Vpr is short for viral protein r, where r is undefined. (12 Dec 1998) |
| gene products, vpu | Non-glycosylated, membrane-associated, 16 kD proteins which are expressed in large amounts in cells infected with HIV-1. The proteins are required for efficient virion maturation and release. They are not present in HIV-2 nor in siv. Vpu is short for viral protein u, with u undefined. (12 Dec 1998) |
| meat products | Articles of food which are derived by a process of manufacture from any portion of carcasses of any animal used for food (e.g., head cheese, sausage, scrapple). (12 Dec 1998) |
| glycosylation end products, advanced | Products derived from the nonenzymatic reaction of glucose and proteins in vivo that exhibit a yellow-brown pigmentation and an ability to participate in protein-protein cross-linking. These substances are involved in biological processes relating to protein turnover and it is believed that their excessive accumulation contributes to the chronic complications of diabetes mellitus. (12 Dec 1998) |
| waste products | Debris resulting from a process that is of no further use to the system producing it. The concept includes materials discharged from or stored in a system in inert form as a by-product of vital activities. (12 Dec 1998) |
| conventional forest products | Any commercial roundwood product (boards, dimension lumber, pulp and paper products) except fuelwood. (05 Dec 1998) |
| poultry products | Food products manufactured from poultry. (12 Dec 1998) |
| household products | Substances or materials used in the course of housekeeping or personal routine. (12 Dec 1998) |
| specialty chemicals and products | Chemicals and chemical products used in a research, industrial, or household setting. Included here are the specific drug preparations, as well as the substances involved in the manufacture and stabilization of pharmaceutical preparations and agricultural agents. (12 Dec 1998) |
| natural products | Naturally occurring compounds that are end products of secondary metabolism; often, they are unique compounds for particular organisms or classes of organisms. (05 Mar 2000) |
| dairy products | Raw and processed or manufactured milk and milk-derived products. These are usually from cows (bovine) but are also from goats, sheep, reindeer, and water buffalo. (12 Dec 1998) |
| orphan products | Drugs, biologicals, and medical devices (including diagnostic in vitro tests) that may be useful in common or rare diseases but which are not considered commercially viable. Synonym: orphan drugs. (05 Mar 2000) |
| fibrin degradation products | <haematology, investigation> A test that measures fibrin degradation products which result from the dissolution of a blood clot. Normal value is less than 10 mcg/ml (micrograms per millilitre). They may be increased in conditions such as burns, placental abruption, heart disease, DIC, after massive blood transfusion, hypoxia, intrauterine foetal death, portacaval shunt, leukaemia, transfusion reaction, transplant rejection, sepsis, renal failure and preeclampsia. Acronym: FDP (23 Sep 2002) |
| fibrin fibrinogen degradation products | <chemical> Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. Fdp and their complexes profoundly impair the haemostatic process and are a major cause of haemorrhage in intravascular coagulation and fibrinolysis. Pharmacological action: antithrombins. (12 Dec 1998) |